Jim B. Farinholt

PharmaNetics, Inc. is a holding company incorporated as the parent company of Cardiovascular Diagnostics, Inc. Cardiovascular Diagnostics develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. Cardiovascular Diagnostics is also establishing itself in the emerging field of theranostics or rapid near-patient testing. PharmaNetics, Inc. was founded in 1998 and is located in Raleigh, NC

Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.

PluroGen Therapeutics LLC provides clinically advanced and advantaged burn, wound and skin care products. The firm also provides online ordering services. PluroGen Therapeutics was founded by George T. Rodeheaver and Adam J. Katz in February 2003 and is headquartered in Norristown, PA.

DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications.

Tall Oaks Capital Partners LLC (Tall Oaks Capital) is a venture capital firm founded in 2000. The firm is headquartered in Charlottesville, Virginia.

The Virginia Biotechnology Research Park operates a pharmaceutical and biotechnology corridor. The private company is based in Richmond, VA. Chandra Briggman has been the CEO of the company since 2020.

Galleher & Co. provides brokerage and other financial services.

Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA.